Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-05 7:53 pm Unchanged | 2024-02-05 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 110,321,886 61.800% | 0 (Unchanged) | Filing History |
| 2023-12-21 3:32 pm Purchase | 2023-11-27 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 110,321,886 61.800% | 58,190,632 (+111.62%) | Filing History |
| 2023-07-03 6:39 pm Purchase | 2023-06-29 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 52,131,254 75.040% | 21,855,950 (+72.19%) | Filing History |
| 2023-06-16 4:20 pm Purchase | 2023-06-01 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 30,275,304 52.850% | 11,508,672 (+61.33%) | Filing History |
| 2022-09-22 3:03 pm Sale | 2022-08-24 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 18,766,632 45.700% | -533 (-0.00%) | Filing History |
| 2022-09-14 3:25 pm Sale | 2022-08-24 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 18,767,165 45.700% | -10,139 (-0.05%) | Filing History |
| 2022-09-09 5:59 pm Purchase | 2022-08-24 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 18,777,304 45.700% | 8,491,133 (+82.55%) | Filing History |
| 2022-04-22 2:58 pm Purchase | 2022-04-10 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 10,286,171 31.600% | 54,957 (+0.54%) | Filing History |
| 2021-07-23 4:27 pm Unchanged | 2021-07-08 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 10,231,214 32.800% | 0 (Unchanged) | Filing History |
| 2021-06-15 11:46 am Unchanged | 2021-06-01 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 10,231,214 32.800% | 0 (Unchanged) | Filing History |
| 2021-04-05 5:00 pm Purchase | 2021-04-02 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 10,231,214 33.300% | 267,530 (+2.69%) | Filing History |
| 2021-03-11 5:07 pm Unchanged | 2021-03-11 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 9,963,684 33.330% | 0 (Unchanged) | Filing History |
| 2021-03-05 5:24 pm Purchase | 2021-03-02 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 9,963,684 33.330% | 1,906,383 (+23.66%) | Filing History |
| 2020-12-29 4:15 pm Unchanged | 2020-12-23 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 8,057,301 30.200% | 0 (Unchanged) | Filing History |
| 2020-09-02 5:18 pm Purchase | 2020-08-30 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 8,057,301 30.000% | 5,000 (+0.06%) | Filing History |
| 2020-02-26 4:35 pm Purchase | 2020-02-13 | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 8,052,301 33.200% | 2,373,529 (+41.80%) | Filing History |